ARP-2853刚地弓形虫低水平乙胺嘧啶抗性质粒(pDHFR-TSc3/M3),在大肠杆菌中重组(质粒/载体）
产品图片
货号/SKU
ARP-2853
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、1
产品描述信息
ARP-2853?? Toxoplasma gondii Low-Level Pyrimethamine-Resistance Plasmid (pDHFR-TSc3/M3), Recombinant in Escherichia coli(Plasmid/Vectors)|Toxoplasma gondii|Toxoplasma gondii Low-Level Pyrimethamine-Resistance Plasmid (pDHFR-TSc3/M3), Recombinant in Escherichia coli|-60°C or colder?|DS Roos, EO KendallAcknowledgment for publications should read “The following reagent was provided by the NIH AIDS Reagent Program for distribution by BEI Resources, NIAID, NIH: Toxoplasma gondii Low-Level Pyrimethamine-Resistance Plasmid (pDHFR TSc3/M3), Recombinant in Escherichia coli, ARP 2853, contributed by Dr. David S. Roos."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
ARP-2853 is an Escherichia coli (E. coli) DH5α stock containing a plasmid, pDHFR-RSc3/M3 (also referred to as pDHFR-RSc3/T83N), which confers low-level resistance to pyrimethamine. The Toxoplasma gondii dihydrofolate reductase-thymidylate synthase (T. gondii dhfr-ts) minigene, with the 5’ genomic flanking sequence fused to cDNA, was cloned into the pKS- polylinker HindIII-EcoRI sites. An additional EcoRI site occurs near the dhfr-ts junction. The vector BamHI site has been filled. The wild-type dhfr-ts coding sequence contains a Thr83(ACC)-Asn(AAC) mutation that confers low-level pyrimethamine resistance to transfected parasites. This mutation is analogous to Ser108-Asn in fansidar-resistant Plasmodium falciparum.
ARP-2853 is suitable for stable transformation of T. gondii. Transformants should be isolated at low frequency (-4), and will typically contain multiple chromosomal or episomal transgenes, with a copy number roughly proportional to selection pressure. Linked genes may be co-amplified along with the selectable marker.
Note: This plasmid confers resistance to pyrimethamine in T. gondii, rendering traditional pyrimethamine/sulfa therapy ineffective. In the event of accidental infection, alternative treatment (e.g., clindamycin and sulfa) should be administered immediately. Transgenic parasites harboring pyrimethamine resistance genes are not to be introduced into animals.
Each vial contains approximately 500 ?L of E. coli DH5α with pDHFR-TSc3/M3 plasmid in Luria Bertani (LB) broth supplemented with 10% glycerol.
ARP-2853 is an Escherichia coli (E. coli) DH5α stock containing a plasmid, pDHFR-RSc3/M3 (also referred to as pDHFR-RSc3/T83N), which confers low-level resistance to pyrimethamine. The Toxoplasma gondii dihydrofolate reductase-thymidylate synthase (T. gondii dhfr-ts) minigene, with the 5’ genomic flanking sequence fused to cDNA, was cloned into the pKS- polylinker HindIII-EcoRI sites. An additional EcoRI site occurs near the dhfr-ts junction. The vector BamHI site has been filled. The wild-type dhfr-ts coding sequence contains a Thr83(ACC)-Asn(AAC) mutation that confers low-level pyrimethamine resistance to transfected parasites. This mutation is analogous to Ser108-Asn in fansidar-resistant Plasmodium falciparum.
ARP-2853 is suitable for stable transformation of T. gondii. Transformants should be isolated at low frequency (-4), and will typically contain multiple chromosomal or episomal transgenes, with a copy number roughly proportional to selection pressure. Linked genes may be co-amplified along with the selectable marker.
Note: This plasmid confers resistance to pyrimethamine in T. gondii, rendering traditional pyrimethamine/sulfa therapy ineffective. In the event of accidental infection, alternative treatment (e.g., clindamycin and sulfa) should be administered immediately. Transgenic parasites harboring pyrimethamine resistance genes are not to be introduced into animals.
Each vial contains approximately 500 ?L of E. coli DH5α with pDHFR-TSc3/M3 plasmid in Luria Bertani (LB) broth supplemented with 10% glycerol.
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.通过此限制的订单将在发货前发送到NIAID进行批准. ARP-2853是一个大肠杆菌 （例如COLI）
含有质粒的DH5α库存，
PDHFR-RSC3 / M3（也称为PDHFR-RSC3 / T83N），其赋予低级
抗吡米甲胺的抗性.＆nbsp; ＆nbsp; 弓形> agondii＆nbsp; 二氢酚酸还原酶 - 胸苷合酶（t.
Gondii DHFR-TS） 小烯，其中5'基因组侧翼
融合到cDNA的序列，被克隆到PKS- polylinker 后 ECO- ECO RI中
网站.另一个 ECO RI网站
发生在 DHFR-TS＆NBSP附近; 结.
Vector BAM HI网站已被填充.野生型 DHFR-TS 编码序列
含有Thr83（ACC）-ASN（AAC）突变，赋予低水平的吡米甲胺
抗转染寄生虫.
该突变类似于抗性抗性抗血糖抗疟原虫的SER108-ASN
Falciparum . ARP-2853
适用于 T的稳定变换. Gondii .转化体应低于低位
频率（-4），通常含有多种染色体或重组
转基因，拷贝数大致与选择压力成比例.链接基因可以共同扩增
可选标记. 注意：这种质粒赋予抵抗力
在 t中的吡米汀Gondii ，
呈现传统吡米甲胺/磺胺疗法无效.如果发生意外感染，替代方案
应立即给予治疗（例如，Clindamycin和Sulfa）.转基因寄生虫含吡米甲胺
不会将抗性基因引入动物中. 每个小瓶包含大约500μl的 e. COLI DH5α，具有PDHFR-TSC3 / M3
Luria Bertani（LB）浆液质粒补充有10％甘油的肉汤.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2022-04-01
2022-04-01
2022-08-11
2021-12-21
2021-12-13
2022-06-17
2022-01-10
2022-06-17
2022-04-01
2022-04-01
2024-01-21
2022-03-31